Table 4 Managements
From: Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study
Variables | All patients (n = 226) |
|---|---|
Respiratory support | |
 None | 11 (4.9%) |
 Oxygen delivery by nasal cannula | 59 (26.1%) |
 Oxygen delivery by mask | 14 (6.2%) |
 High-flow nasal cannula (HFNC) | 37 (16.4%) |
 Noninvasive mechanical ventilation | 20 (8.8%) |
 Invasive mechanical ventilation | 85 (37.6%) |
 ECMO | 14 (6.2%) |
Prone position | 22 (9.7%) |
Continuous renal replacement therapy | 24 (10.6%) |
Vasoactive drugs | 48 (21.2%) |
Intravenous antihypertensive drugs | 14 (6.2%) |
Central venous catheterization | 22 (9.7%) |
Thoracic cavity closed drainage | 1 (0.4%) |
Accidental removal of tracheal tube | 2 (0.9%) |
Spontaneous breathing test | 17 (7.5%) |
 Spontaneous breathing test (failed) | 15 (6.6%) |
 Spontaneous breathing test (passed) | 2 (0.9%) |
Removal of tracheal tube | 1 (0.4%) |
Chest imaging examination | 56 (24.8%) |
Ultrasound examination | 63 (27.9%) |
 Chest or lung ultrasound examination | 52 (23.0%) |
Antivirus agent | 117 (51.8%) |
 Ribavirin | 35 (15.49%) |
 Ganciclovir | 6 (2.65%) |
 Interferon inhalation | 9 (3.98%) |
 Arbidol | 51 (22.57%) |
 Lopinavir-ritonavir | 12 (5.31%) |
 Neuaminidase inhibitors | 10 (4.42%) |
Thymosin | 92 (40.7%) |
Antimicrobial agents | 168 (74.3%) |
Systemic glucocorticoids | 37 (16.4%) |
Immunoglobulin | 29 (12.8%) |
Blood transfusion | 19 (8.4%) |
 Red blood cell | 11 (4.9%) |
 Plasma | 9 (4.0%) |
 Blood platelet | 1 (0.4%) |
Traditional Chinese herb | 59 (26.1%) |